Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story 3 Undervalued Names Too Cheap to IgnoreReported by Nathan Reiff. Date Posted: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 seem like an unlikely time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below all represent potential value plays, with valuation metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, including compelling dividends or promising product developments. While value opportunities can be harder to find when many high-quality names are back in investor favor — and some apparent bargains have deteriorating operations or other red flags — well-established, stable names can still present value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Decades ago, Washington sold the American public on ditching cash for credit cards to protect us from theft and stop criminals, but instead of stopping crime, it gave the government an unprecedented window into our daily lives—every flight, restaurant, and gallon of gas leaving a permanent data trail. Through a new initiative outlined in Federal Reserve Docket No. OP-1670, known as FedNow, the government is rolling out the ultimate financial tracking web that routes all those fragmented private transactions through a single centralized hub operated by the Federal Reserve itself, giving the federal government real-time 24/7 visibility into virtually every dollar moving through the U.S. economy with the power to flag or freeze your money with a single keystroke. Get the 4 steps to Fed-proof your savings now Although shares have climbed more than 28% over the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45 — well below the medical industry average of close to 27. Analysts expect continued growth: earnings are projected to rise nearly 10% in the coming year, and the stock shows about 5% additional upside in the near term. Helping to drive Merck's momentum is its pembrolizumab cancer drug, Keytruda, which gained approval for subcutaneous injection from the European Commission in late 2025 and reached roughly $8.4 billion in sales in Q4 2025 — an increase of about 7% year-over-year. Keytruda is also showing potential in ovarian cancer, which could expand its patient base and support revenue as Merck prepares for Keytruda's loss of patent exclusivity in 2028. Merck's portfolio is broadening beyond oncology. The company recently announced phase 3 trial results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck is restructuring its human health operations into two units to more easily grow non-cancer-drug sales as it plans for Keytruda's eventual generics competition. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share (EPS) fell 13%. Margin improvement has been limited so far despite cost-saving measures. The near term is likely to remain challenging for the iconic brand, and fiscal-year guidance is weak overall. Still, Campbell's improving supply chain and strong brand loyalty — particularly for its premium offerings — should provide some protection. Shifting tariff dynamics could also ease pressure over time. On top of that, Campbell's remains an attractive dividend play, with a yield of 5.9%, although its payout ratio is relatively high at over 80%. Its P/E ratio of 13.5 is the lowest in about four years. Those factors may persuade some investors that the stock is worth considering despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has followed almost the opposite trajectory of Campbell's — shares have climbed roughly 33% over the last year. Even so, its P/E ratio remains reasonable relative to certain benchmarks at 31.6. On the fundamentals, US Foods is making important strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year-over-year. Better inventory management and cost-of-goods savings are helping the firm gain traction. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue growth and continue expanding adjusted EBITDA. Analysts view USFD as a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential.
| 
